Lambert Eaton Myasthenic Syndrome (LEMS) (DBCOND0053084)
Identifiers
- Synonyms
- Eaton-Lambert Myasthenic Syndrome / Lambert Eaton Myasthenic Syndrome / Lambert-Eaton Myasthenic Syndrome (LEMS) / Lambert-Eaton Myasthenic Syndrome / Lambert-Eaton syndrome in neoplastic disease / Lambert-Eaton syndrome, unspecified / Eaton-Lambert syndrome (disorder) / Eaton-Lambert syndrome / Myasthenic syndrome
Associated Data
- Indicated Drugs and Targets
Drug Description Targets Amifampridine A voltage gated potassium channel blocker used to treat Lambert-Eaton myasthenic syndrome.Guanidine A strong organic base used to treat muscle weakness and fatigue associated with the myasthenic complications of Eaton-Lambert syndrome.- Ribonuclease pancreatictarget
- DNAtarget
- Disks large homolog 4target
- Endolysintarget
- Aldehyde dehydrogenase, mitochondrialtarget
- Guanidinoacetate N-methyltransferasetarget
- Arginasetarget
- Solute carrier family 22 member 2transporter
- Solute carrier family 22 member 1transporter
- Solute carrier family 22 member 3transporter
- Organic cation/carnitine transporter 2transporter
- Organic anion transporter 3transporter
- Solute carrier family 22 member 4transporter
- Multidrug and toxin extrusion protein 1transporter
- Multidrug and toxin extrusion protein 2transporter
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT01511978 Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome treatment 2 completed NCT00704925 Treatment of Lambert-Eaton Syndrome With 3,4 DAP Not Available Not Available no_longer_available NCT01377922 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) treatment 3 completed NCT00716066 Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases treatment 2 active_not_recruiting NCT01825395 Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome No drug interventions Not Available Not Available approved_for_marketing NCT01378546 Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP Not Available Not Available no_longer_available NCT02012933 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM) Not Available Not Available no_longer_available NCT05408702 Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes No drug interventions Not Available Not Available completed NCT01373333 Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome Not Available Not Available no_longer_available NCT00994916 Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine Not Available Not Available no_longer_available NCT00004832 Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome treatment Not Available completed NCT06441825 Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis No drug interventions Not Available Not Available recruiting NCT02189720 Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome Not Available Not Available no_longer_available NCT02970162 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) treatment 3 completed NCT00872950 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS) Not Available Not Available approved_for_marketing